E. Clini (Pavullo, Italy), Y. G. Kilinc (Istanbul, Turkey)
Change in breathlessness and symptom scores during hospitalisation with exacerbations of COPD
N. Duffy, F. Diamantea, P. Walker, P. M. A. Calverley, L. Davies (Liverpool, United Kingdom)
|  |
Changes parameters of non-specific immune defence during COPD exacerbation
J. A. Mikryukova, G. L. Ignatova, S. N. Teplova, E. V. Davydova (Chelyabinsk, Russia)
| |
Comparative evaluation of fluoroquinolone efficiency in treatment of infectious acute attack of chronic obstructive bronchitis
L. V. Yudina, V. I. Snezhko, Y. V. Rachko (Kiev, Ukraine)
| |
The ICE study, Italian costs for exacerbations in COPD: regional variations in admission criteria and diagnosis related group coding
C. F. Donner, M. Lusuardi, F. De Benedetto, C. Lucioni, S. Mazzi, P. L. Paggiaro, C. Sanguinetti (Veruno, Correggio, Chieti, Milan, Pisa, Roma, Italy)
| |
Analysis of the costs of COPD in patients admitted in 2002 in ²M. Nasta² Institute of Pulmonology
I. R. Strambu, D. Nicolescu, S. Bucsa, C. Dumitrescu, I. P. Stoicescu, B. Grigoriu (Bucharest, Romania)
| |
Infective etiology of acute exacerbation of COPD (AECOPD)
L. Erkan, O. Uzun, D. Katar, A. Saniç, S. Findik, A. G. Atici (Samsun, Turkey)
| |
Predicting factors for an exacerbation in patients with COPD during one year treatment with salmeterol/fluticasone or salmeterol
E. C. Creutzberg, D. S. Postma, W. C. J. Hop, N. A. Vermue, E. F. M. Wouters (Maastricht, Groningen, Rotterdam, Zeist, The Netherlands)
| |
Chronic obstructive pulmonary disease exacerbation and gastro-esophageal reflux symptoms
S. V. Raljevic, M. Mitic-Milikic (Belgrade, Serbia & Montenegro)
| |
Tiotropium reduces COPD exacerbations: the MISTRAL study
D. Dusser, M. L. Bravo, P. Iacono on Behalf of the MISTRAL Study Group (Paris, Reims, France)
| |
Tiotropium reduces health resource utilization associated with COPD exacerbations
D. Dusser, M. L. Bravo, P. Iacono on Behalf of the MISTRAL Study Group (Paris, Reims, France)
| |
Left ventricular dysfunction as a precipitating factor of acute respiratory failure (ARF) in COPD patients
S. N. Avdeev, A. G. Chuchalin (Moscow, Russia)
| |
Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD
M. K. Hunjan, D. T. Williams (Uxbridge, United Kingdom)
| |
Important attributes of COPD exacerbations: a conjoint analysis
J. Haughney, C. Vogelmeier, R. Kessler, M. R. Partridge, E. Ståhl (Aberdeen, London, United Kingdom; Marburg, Germany; Strasbourg, France; Lund, Sweden)
| |
Patient’s knowledge about risk factors for acute exacerbation( AE ) of chronic obstructive pulmonary disease( COPD )
L. Nagorni Obradovic, V. Petrovic, M. Mitic-Milikic (Belgrade, Serbia & Montenegro)
| |
What public know about chronic obstructive pulmonary disease (COPD) in Turkey? Results of a questionnaire survey done on world COPD day 2003
E. Uzaslan, D. Ediger, F. Coskun, B. Erdogan, Z. Yavuz, E. Rodoplu, O. Ozkubat, H. Gocmen, E. Demirdogen, B. Onal, O. Akbaba, A. Ursavas, M. Karadag, E. Ege, O. Gozu (Bursa, Turkey)
| |
The 6-min walk distance significance in COPD diagnostic
G. L. Ignatova, J. A. Mikryukova, I. V. Drosdov (Chelyabinsk, Russia)
| |
The value of exercise testing to the early diagnosis of COPD
G. Ulubay, A. Simsek, I. Yilmaz, O. Karacan, F. O. Eyüboglu (Ankara, Turkey)
| |
Early diagnostics of COPD
L. V. Belenko, I. V. Leshchenko (Ekaterinburg, Russia)
| |
Underdiagnosis of COPD and impact of a new diagnostic questionnaire
D. Price, D. G. Tinkelman, R. J. Nordyke, S. Isonaka, R. J. Halbert (Aberdeen, United Kingdom; Denver, Beverly Hills, United States Of America)
| |